NightHawk Biosciences, Inc.
(NYSE Amex Equities : HTBX)

( )
HTBX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.07%166.350.7%$1322.99m
LLYEli Lilly & Co. -0.29%333.201.1%$1039.75m
PFEPfizer Inc. -0.28%44.270.9%$799.00m
BMYBristol-Myers Squibb Co. 0.00%72.061.0%$784.71m
ABBVAbbVie, Inc. -0.58%143.721.9%$777.17m
MRKMerck & Co., Inc. -0.82%86.080.7%$697.20m
AZNAstraZeneca Plc -0.70%54.311.0%$434.02m
NVSNovartis AG -1.43%75.220.2%$218.10m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%210.768.2%$210.83m
GSKGSK Plc -0.76%29.230.3%$204.46m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.115.4%$190.67m
NVONovo Nordisk A/S 1.29%100.660.1%$177.86m
HZNPHorizon Therapeutics Plc -0.55%63.495.4%$169.03m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.42%151.310.0%$157.49m
SGENSeagen Inc. 0.00%137.725.7%$129.81m

Company Profile

NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.